Kidney International Reports最新文献

{"title":"The Immune Microenvironment of Transplant Glomerulitis","authors":"Nathan A. Bracey ,&nbsp;Jonathan S. Maltzman ,&nbsp;Adrienne H. Long ,&nbsp;Renu Dhanasekaran ,&nbsp;Vishnu Shankar ,&nbsp;Azam Mohsin ,&nbsp;Neeraja Kambham ,&nbsp;Gerlinde Wernig ,&nbsp;Andrew J. Gentles ,&nbsp;Mark M. Davis ,&nbsp;Vivek Charu","doi":"10.1016/j.ekir.2025.06.015","DOIUrl":"10.1016/j.ekir.2025.06.015","url":null,"abstract":"<div><h3>Introduction</h3><div>Transplant glomerulitis is a morphological lesion seen in kidney allograft rejection that is associated with poor outcomes; however, little is known about how immune cells infiltrate and organize specifically within glomeruli.</div></div><div><h3>Methods</h3><div>We used Co-Detection by Indexing (CODEX) multifluorescent imaging to measure 52 protein markers in a retrospective cohort of 41 human allograft nephrectomies (ANs) and evaluated the immunological landscape of transplant glomerulitis.</div></div><div><h3>Results</h3><div>Characterization of 18 cell types identified diverse immune cells within inflamed glomeruli, with unique phenotypes and compositions compared with the extraglomerular microenvironment. Immunological phenotypes were conserved across glomeruli within individuals and associated with the general state of injury, with M1 macrophages and effector CD8 T cells associated with mild inflammation. Distance-based spatial analysis further revealed a profibrotic community composed of M2 macrophages, memory CD8 T cells and exhausted CD8 T cells surrounding endothelial cell hubs. These interaction networks were associated with regions of adverse glomerular remodeling, expression of profibrotic proteins, and were more prevalent in individuals with C4d-positive rejection.</div></div><div><h3>Conclusion</h3><div>These results implicate distinct cell-cell interactions as hallmarks of alloimmune injury and chronic remodeling during transplant glomerulitis and may give rise to new tools for histological risk assessment of clinical rejection syndromes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3113-3127"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation","authors":"Delphine Kervella ,&nbsp;Franc Casanova-Ferrer ,&nbsp;Camille N. Kotton ,&nbsp;Laura Donadeu ,&nbsp;Deepali Kumar ,&nbsp;Silvia Pineda ,&nbsp;Elena Crespo ,&nbsp;Maria Meneghini ,&nbsp;José González-Costelo ,&nbsp;Elena García-Romero ,&nbsp;Laura Lladó ,&nbsp;Alba Cachero ,&nbsp;Edoardo Melilli ,&nbsp;Irina B. Torres ,&nbsp;Anna Martínez-Lacalle ,&nbsp;Zaira Castañeda ,&nbsp;Mónica Martinez-Gallo ,&nbsp;Oscar Len ,&nbsp;Ibai Los-Arcos ,&nbsp;Enric Trilla-Herrera ,&nbsp;Oriol Bestard","doi":"10.1016/j.ekir.2025.06.056","DOIUrl":"10.1016/j.ekir.2025.06.056","url":null,"abstract":"<div><h3>Introduction</h3><div>The interferon gamma (IFN-γ) enzyme-linked immunosorbent spot is a highly sensitive immune assay that enables the assessment of cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) and can identify at-risk transplant patients of CMV infection; however, its clinical implementation remains elusive.</div></div><div><h3>Methods</h3><div>We developed a novel CMV-CMI risk-score based on the standardized T-SPOT.CMV assay against 2 CMV antigens (immediate-early protein 1 [IE-1] and 65 kDa phosphoprotein [pp65]), a biomarker predicting CMV infection, both high viral replication, and disease by performing a pooled analysis of 570 kidney transplants participating in different clinical trials and subsequently validating it in 146 consecutives solid organ transplants (SOT) in an interventional trial. By incorporating clinical variables into the CMV-CMI risk-score, we built an integrative prognostic system quantifying the risk of CMV infection (CMV-PrognosTIC score) using elastic net penalized regression analysis.</div></div><div><h3>Results</h3><div>In the pooled derivation cohort, whereas specific IE-1/pp65-specific CMV-CMI frequencies independently correlated with high risk of CMV infection (areas under the curve [AUCs]: 0.694, <em>P</em> &lt; 0.0001; 0.719, <em>P</em> &lt; 0.0001, respectively), by combining both responses, 3 CMV-CMI risk-scores appeared, accurately discriminating low-risk (LR) from intermediate-risk (IR) and high-risk (HR) patients (98.7% negative predictive value [NPV], 97.2% sensitivity). Its prospective implementation guiding decision-making in an independent SOT cohort confirmed the very high NPV and sensitivity identifying LR patients. By integrating type of preventive therapy, patient age, and donor (D) and recipient (R) CMV-serostatus to the CMV-CMI risk-score, we generated a global risk-prognostic model showing accurate discrimination and calibration in both derivation (AUC: 0.807) and validation cohorts (AUC: 0.719).</div></div><div><h3>Conclusion</h3><div>We developed a robust CMV-PrognosTIC score to quantify the risk of CMV infection in SOT, which may be readily implemented in clinical transplantation to personalize CMV preventive therapies.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3044-3057"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes After Kidney Transplantation in Antiglomerular Basement Membrane Disease","authors":"Priscille Traversat ,&nbsp;Marine Dekervel ,&nbsp;Christophe Masset ,&nbsp;Dominique Bertrand ,&nbsp;Léonard Golbin ,&nbsp;Philippe Gatault ,&nbsp;Antoine Thierry ,&nbsp;Emilie Cornec-Le Gall ,&nbsp;Maïté Jaureguy ,&nbsp;Cyrille Garrouste ,&nbsp;Dany Anglicheau ,&nbsp;Valérie Chatelet ,&nbsp;Sophie Caillard ,&nbsp;Anna Duval ,&nbsp;Jean-Philippe Rerolle ,&nbsp;Martin Planchais ,&nbsp;Agnès Duveau ,&nbsp;Fabien Duthe ,&nbsp;Jean-François Augusto ,&nbsp;Benoît Brilland","doi":"10.1016/j.ekir.2025.06.021","DOIUrl":"10.1016/j.ekir.2025.06.021","url":null,"abstract":"<div><h3>Introduction</h3><div>Goodpasture disease, or antiglomerular basement membrane (anti-GBM) disease, is a rare autoimmune disorder that often leads to end-stage kidney disease (ESKD). Although kidney transplantation (KT) is the preferred treatment, concerns exist about disease recurrence and graft outcomes in patients with GBM-associated glomerulonephritis (GBM-GN). This study aimed to evaluate posttransplant outcomes in patients with GBM-GN compared with matched controls.</div></div><div><h3>Methods</h3><div>This retrospective, multicenter study included 100 patients with anti-GBM who received KT between 2005 and 2023 in 13 French transplant centers, matched with 200 control recipients. We compared the incidence of delayed graft function (DGF), graft failure, relapse, acute rejection, and death between groups and analyzed risk factors using multivariable models.</div></div><div><h3>Results</h3><div>No significant differences in DGF incidence (22% vs. 19%, <em>P</em> = 0.5), graft survival (87% vs. 88% at 5 years, <em>P</em> = 0.4), or patient survival (93% vs. 89% at 5 years, <em>P</em> = 0.4) were found between patients with GBM-GN and controls. Patients with GBM-GN tended to have lower risk of acute rejection (hazard ratio [HR] = 0.51, 95% confidence interval: 0.25–1.02, <em>P</em> = 0.055). Only 1 patient with GBM-GN (1%) experienced disease relapse. Although patients with GBM-GN were waitlisted and transplanted later than controls, specific transplant timing was not associated with improved outcomes.</div></div><div><h3>Conclusion</h3><div>KT in patients with GBM-GN offers comparable outcomes to other nephropathies in the current era. Disease relapse is rare, even in the few patients with detectable antibodies pretransplantation. The lower incidence of acute rejection in the GBM-GN group warrants further investigation. These findings support KT as a viable option in patients with GBM-GN, though specific pre- and posttransplant monitoring is advised.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3150-3163"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-Reported Outcome of Living Kidney Donation Correlates With Perioperative Complications not With Surgical Techniques","authors":"Martina Koch ,&nbsp;Jeannine Wegner ,&nbsp;Eike Bormann ,&nbsp;Sylvia Kröncke ,&nbsp;Sarah Riepenhausen ,&nbsp;Philipp Neuhaus ,&nbsp;Julian Varghese ,&nbsp;Joachim Gerß ,&nbsp;Claudia Sommerer ,&nbsp;Barbara Suwelack","doi":"10.1016/j.ekir.2025.06.052","DOIUrl":"10.1016/j.ekir.2025.06.052","url":null,"abstract":"<div><h3>Introduction</h3><div>The German health care system lacks data on surgical complications and self-reported outcomes (SROs) of living donors. The prospective German Living Kidney Donor Registry, SOLKID-GNR aims to improve the assessment of donors’ medical and psychosocial risks.</div></div><div><h3>Methods</h3><div>Data were collected before (PRE) and 3 months after (POST) living kidney donation from transplantation centers (TCs) and donors via SROs. We reported perioperative complication rates for different surgical techniques and correlated them with donors’ SROs. Datasets of 1020 donors from 30 German TCs were analyzed.</div></div><div><h3>Results</h3><div>Donor nephrectomy procedures included laparoscopic (57.9%), retroperitoneoscopic (21.4%), open retroperitoneal (16.0%), or open abdominal nephrectomy (4.7%). Perioperative complications reported by TCs ranged from 9.8% (retroperitoneoscopic) to 17.1% (open abdominal), whereas those reported by donors ranged from 12.2% (open retroperitoneal) to 15.0% (open abdominal). Donors were discharged sooner and returned to work earlier after minimally invasive surgery; however, had comparable quality-of-life (QoL) after donation. The physical component summary (PCS) scores of the Short Form–12 (SF-12) were similar between the 4 surgical methods postdonation; however, they were lower in donors with TC- or self-reported complications than in those without. The mental component summary (MCS) scores of the SF-12 were lower in case of self-reported complications only. Despite 12.5% of self-reported complications, 96.4% expressed a willingness to donate again, and 94.1% felt well-informed.</div></div><div><h3>Conclusion</h3><div>Although the surgical technique does not directly affect donors' QoL shortly after donation, minimally invasive procedures result in shorter hospital stays and a quicker return to work. Self-reported complications have a greater impact on mental QoL than those documented by transplant centers, highlighting the importance of subjective experiences during recovery.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3058-3069"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Normothermic Kidney Perfusion: Current Status and Future Perspectives","authors":"Barbara Franchin ,&nbsp;Leonie van Leeuwen ,&nbsp;Matthew L. Holzner ,&nbsp;Nicholas Chun ,&nbsp;Lucrezia Furian ,&nbsp;Paolo Cravedi","doi":"10.1016/j.ekir.2025.06.041","DOIUrl":"10.1016/j.ekir.2025.06.041","url":null,"abstract":"<div><div>Normothermic machine perfusion (NMP), the most recent advancement in solid organ preservation, enables <em>ex situ</em> maintenance of grafts in a physiologically active state, offering a significant advantage over traditional cold storage methods. Whereas NMP is now widely adopted for clinical preservation of livers, hearts, and lungs, its application in kidney transplantation remains relatively limited. In this context, NMP holds promise for expanding the use of marginal donor kidneys by enhancing viability assessment and potentially restoring function in grafts that might otherwise be discarded. In addition, NMP provides a valuable platform for studying molecular markers of injury and recovery in human organs, as well as for delivering targeted therapies aimed at modulating immunologic or transcriptomic profiles. Despite its potential, broader clinical implementation is hindered by variability in perfusion devices, protocols, and perfusate compositions across centers, making cross-study comparisons challenging. This review examines the current landscape of kidney NMP and its emerging role in graft reconditioning.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 2943-2952"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review and Network Meta-Analysis of Initial Treatments for Lupus Nephritis","authors":"Ariel Izcovich ,&nbsp;Fernando Tortosa ,&nbsp;Agustín Bengolea ,&nbsp;Moira Magdalena Pissinis ,&nbsp;Martín Ragusa ,&nbsp;Mariano Fielli ,&nbsp;Camila Agnoletti ,&nbsp;Rosana Quintana ,&nbsp;Ana Malvar ,&nbsp;Marina Scolnik ,&nbsp;Eloisa Bonfá ,&nbsp;Eduardo F. Borba ,&nbsp;Odirlei Andre Monticielo ,&nbsp;Edgard Torres dos Reis-Neto ,&nbsp;Loreto Massardo ,&nbsp;José A. Gómez-Puerta ,&nbsp;Carlos Enrique Toro-Gutiérrez ,&nbsp;Jorge A. Esquivel-Valerio ,&nbsp;Hilda Fragoso Loyo ,&nbsp;Juan Manuel Mejia-Vilet ,&nbsp;Guillermo Pons-Estel","doi":"10.1016/j.ekir.2025.06.047","DOIUrl":"10.1016/j.ekir.2025.06.047","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to evaluate the comparative efficacy and safety of various initial treatments for active lupus nephritis (LN) through a systematic review and network meta-analysis (NMA).</div></div><div><h3>Methods</h3><div>We conducted a comprehensive literature search across multiple databases from inception to February 2025 to identify randomized controlled trials (RCTs) comparing initial treatments for LN. We performed a frequentist random-effects NMA using the restricted maximum likelihood method to estimate heterogeneity. We used the GRADE approach to assess the certainty of evidence.</div></div><div><h3>Results</h3><div>We included 40 RCTs encompassing 5450 patients and 16 interventions (12 drugs administered alone or in combination). Mycophenolic acid analogs (MPAAs) were selected as the common comparator. The network meta-analysis revealed that voclosporin (VCS) combined with MPAA (risk difference [RD]: 281.38 more/1000, 95% confidence interval [CI]: 146.26 more to 456.42 more; high certainty), belimumab (BEL) combined with MPAA (RD: 145.02 more/1000, 95% CI: 72.73 more to 230.92 more; high certainty), and obinutuzumab (OBI) combined with MPAA (RD: 134.23 more/1000, 95% CI: 30.37 more to 269.68 more; moderate certainty) increased complete renal response (CRR) compared with MPAA alone. Tacrolimus (TAC) combined with MPAA (RD: 113.69 more/1000, 95% CI: 25.23 more to 217.7 more; low certainty) also showed potential benefits but with low certainty evidence.</div></div><div><h3>Conclusion</h3><div>Combination therapies, particularly VCS, BEL, or OBI with MPAA, provide enhanced outcomes for LN initial treatment. Given the complexity of LN, clinicians should weigh these findings alongside considerations such as drug availability, cost, and individual patient preferences to guide treatment decisions.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 2977-2990"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis of Randomized Controlled Trials on Gamma-Aminobutyric Acid Analogues and Opioid-Based Therapies for CKD-Associated Pruritus","authors":"Wannasit Wathanavasin ,&nbsp;Theerachai Thammathiwat ,&nbsp;Paweena Susantitaphong","doi":"10.1016/j.ekir.2025.06.037","DOIUrl":"10.1016/j.ekir.2025.06.037","url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic kidney disease (CKD)-associated pruritus (CKD-aP) is one of the most distressing symptoms of patients with CKD, adversely affecting their quality of life and survival. This study aimed to investigate the efficacy and safety of gamma-aminobutyric acid (GABA) analogues and opioid-based therapies in patients with CKD-aP.</div></div><div><h3>Methods</h3><div>The eligible studies were searched from PubMed, Embase, and Scopus up to January 22, 2025. Only randomized controlled trials (RCTs) that reported the treatment effect on pruritus severity scores were included, focusing on both unidimensional scales and multidimensional scales. The results were synthesized using a random-effect model and provided weighted mean difference (WMD) and relative risk (RR) with a 95% confidence interval (CI).</div></div><div><h3>Results</h3><div>A total of 27 RCTs involving 2836 patients with CKD-aP were analyzed. Treatment with GABA analogues was associated with significantly greater reductions in 10-cm visual analog scale (VAS) and 5-D itch scores with nonsignificant increased incidence of adverse events (AEs) or adverse drug reactions (ADRs). In addition, opioid receptor–targeting treatments significantly decreased worst itch numeric rating scale (WI-NRS), 5-D itch, Skindex-10, and 100-mm VAS, but showed significantly higher rates of AEs or ADRs, particularly related to gastrointestinal issues, as well as neurological disorders such as sleep disturbances.</div></div><div><h3>Conclusion</h3><div>Our results suggest that GABA analogues and opioid-based therapies, particularly difelikefalin, have significant potential in alleviating itch intensity and improving the quality of life of patients with CKD-aP. However, opioid-based therapies, especially those involving μ-receptor antagonists such as naltrexone and nalbuphine, are associated with a higher incidence of AEs or ADRs. Given the substantial heterogeneity observed in most of the results, interpretation should be approached with caution.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 2991-3005"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulated Anaerobic Glycolysis in Podocytes is Relevant to the Progression of Focal Segmental Glomerulosclerosis","authors":"Masahiro Sugimura ,&nbsp;Kayaho Maeda ,&nbsp;Katsuaki Shibata ,&nbsp;Hiroshi Seko ,&nbsp;Yohei Kozaki ,&nbsp;Akiyoshi Hirayama ,&nbsp;Tomoyoshi Soga ,&nbsp;Takaya Ozeki ,&nbsp;Yuka Sato ,&nbsp;Noritoshi Kato ,&nbsp;Tomoki Kosugi ,&nbsp;Kenji Kadomatsu ,&nbsp;Shoichi Maruyama","doi":"10.1016/j.ekir.2025.06.022","DOIUrl":"10.1016/j.ekir.2025.06.022","url":null,"abstract":"<div><h3>Introduction</h3><div>Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are podocytopathies with varying clinical courses and therapeutic responses. FSGS often leads to end-stage renal disease. Consequently, their heterogeneity requires case stratification and pathophysiological elucidation. The involvement of energy metabolism in FSGS pathogenesis and stratification has not been clarified. Therefore, this study aimed to verify whether evaluating energy kinetics can be a new approach to MCD or FSGS stratification and explore the role of energy metabolism in MCD or FSGS.</div></div><div><h3>Methods</h3><div>Cultured human podocytes were treated with sera from patients with biopsy-confirmed MCD or FSGS. Serum-treated podocytes were analyzed for apoptosis using flow cytometry, metabolomics via mass spectrometry, and real-time adenosine triphosphate (ATP) production rates using an extracellular flux analyzer. Adriamycin-induced nephropathy was induced in podocyte-specific lactate dehydrogenase (LDH) A (LDHA)-deficient and control mice.</div></div><div><h3>Results</h3><div>The sera from patients with FSGS significantly induced apoptosis in human podocytes compared with those from individuals with MCD. Apoptosis severity was associated with segmental obliteration and corticosteroid resistance. Metabolomic analysis revealed differences in anaerobic glycolysis and tricarboxylic acid cycle (TCA)-related metabolites in podocytes exposed to the sera of patients with MCD and FSGS. In the podocytes treated with sera from patients with FSGS, glycolytic ATP production significantly decreased in cases with high apoptosis rates. The sera from patients with FSGS suppressed LDHA activity, suppressed α-actinin 4 (ACTN4) expression, and promoted actin remodeling of podocytes. Segmental sclerosis was more prominent in podocyte-specific LDHA-deficient mice with adriamycin-induced nephropathy than in control mice.</div></div><div><h3>Conclusion</h3><div>FSGS progression was associated with decreased anaerobic glycolysis in podocytes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3239-3254"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Insights Into Renal Involvement During Immune-Mediated Thrombotic Thrombocytopenic Purpura","authors":"Marie Robert ,&nbsp;Valentin Maisons ,&nbsp;Marion Rabant ,&nbsp;Aude Servais ,&nbsp;Charles Antunes ,&nbsp;Nicolas Fage ,&nbsp;Florent von Tokarski ,&nbsp;Sophie Chauvet ,&nbsp;Manon Dekeyser ,&nbsp;Alain Wynckel ,&nbsp;Anna Duval ,&nbsp;Nadine Baroukh ,&nbsp;Agnès Veyradier ,&nbsp;Bérangère S. Joly ,&nbsp;Paul Coppo ,&nbsp;Jean-Michel Halimi","doi":"10.1016/j.ekir.2025.06.039","DOIUrl":"10.1016/j.ekir.2025.06.039","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3271-3275"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the Letter to the Editor Entitled “Desmopressin After Kidney Biopsy: Are the Risks Worth it?”","authors":"Narayan Prasad ,&nbsp;Jeyakumar Meyyappan","doi":"10.1016/j.ekir.2025.07.010","DOIUrl":"10.1016/j.ekir.2025.07.010","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 9","pages":"Pages 3292-3293"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144933961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}